Despite the gains of the last year, Johnson & Johnson (JNJ) hasn't actually outperformed the market. In fact, the stock has now vastly underperformed the market since the start of November and reinforces the valuation questionsthat exist with this healthcare stock and ongoing negative signals from the company.
Struggling Stock
The important story to understand with JNJ or any stock is that relative performance matters. The stock was extremely expensive for the organic growth offered and the stock finally hit a ceiling during the year. JNJ is nearly flat over the last three months as the S&P 500 index has soared.

